Invasive pulmonary aspergillosis real-world outcomes: Clinical features and risk factors associated with increased mortality

被引:12
|
作者
Henao-Martinez, Andres F. [1 ,5 ]
Corbisiero, Michaele Francesco [1 ]
Salter, Ixchel [1 ]
Chastain, Daniel B. [2 ]
Thompson III, George R. [3 ,4 ]
机构
[1] Univ Colorado, Dept Med, Div Infect Dis, Anschutz Med Campus, Aurora, CO 80045 USA
[2] Univ Georgia, Dept Clin & Adm Pharm, Coll Pharm, Albany, GA 31701 USA
[3] Univ Calif Sacramento, Davis Med Ctr, Dept Med, Div Infect Dis, Sacramento, CA 95817 USA
[4] Univ Calif Sacramento, Davis Med Ctr, Dept Med Microbiol & Immunol, Sacramento, CA 95817 USA
[5] Univ Colorado, Anschutz Med Campus, 12700,19th Ave,Mail Stop B168, Aurora, CO 80045 USA
关键词
Aspergillus; invasive pulmonary aspergillosis; mortality; drug therapy; VORICONAZOLE; INFECTIONS; DIAGNOSIS; PHASE-3;
D O I
10.1093/mmy/myad074
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Invasive pulmonary aspergillosis (IPA) is a severe fungal infection that primarily affects immunocompromised patients and is associated with high mortality. Contemporary clinical characteristics of IPA and "real-world" estimates and predictors of associated mortality are inadequate. TriNetX, a global research network, was queried to identify adult patients with IPA diagnoses based on the ICD-10 code B44.0. We performed a propensity score-matched analysis comparing clinical characteristics among patients who survived versus non-survivors at 1 year. We identified 4371 patients with IPA. We found neoplasms, solid organ transplant recipients, hematologic malignancies, and aplastic anemia as the most predominant risk factors. The overall 1-year mortality was 32% for IPA. 1-year mortality was highest for patients with COVID-19 in the ICU, followed by those with acute myeloid leukemia and aplastic anemia (54%, 50%, and 39%, respectively). After propensity score matching, severe sepsis, pleural effusion, and candidiasis were mortality contributors within a year after diagnosis. Liver injury, systemic glucocorticoid exposure over the previous 6 months, lower lymphocyte and CD4 counts, elevated ferritin, LDH, thrombocytopenia, anemia, or elevated glycosylated hemoglobin (HbA1c) were independent predictors of mortality at 1 year. Voriconazole was the most common treatment (67%). The annual incidence of IPA was 0.001%, increasing to 0.02% among critically ill patients in the ICU. IPA continues to have a very high mortality. We encourage prospective studies to validate and refine the identified clinical markers linked to increased mortality. Lay Summary Invasive pulmonary aspergillosis (IPA) is common among immunocompromised patients. Analyzing a global research network, we found 32% of patients with IPA died a year after diagnosis. We identified the primary underlying conditions, contributors, and predictors of mortality.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Mortality risk factors in primary Sjogren syndrome: a real-world, retrospective, cohort study
    Brito-Zeron, Pilar
    Flores-Chavez, Alejandra
    Horvath, Ildiko Fanny
    Rasmussen, Astrid
    Li, Xiaomei
    Olsson, Peter
    Vissink, Arjan
    Priori, Roberta
    Armagan, Berkan
    Hernandez-Molina, Gabriela
    Praprotnik, Sonja
    Quartuccio, Luca
    Inanc, Nevsun
    Ozkiziltas, Burcugul
    Bartoloni, Elena
    Sebastian, Agata
    Romao, Vasco C.
    Solans, Roser
    Pasoto, Sandra G.
    Rischmueller, Maureen
    Galisteo, Carlos
    Suzuki, Yasunori
    Trevisani, Virginia Fernandes Moca
    Fugmann, Cecilia
    Gonzalez-Garcia, Andres
    Carubbi, Francesco
    Jurcut, Ciprian
    Shimizu, Toshimasa
    Retamozo, Soledad
    Atzeni, Fabiola
    Hofauer, Benedikt
    Melchor-Diaz, Sheila
    Gheita, Tamer
    Lopez-Dupla, Miguel
    Fonseca-Aizpuru, Eva
    Giacomelli, Roberto
    Vazquez, Marcos
    Consani, Sandra
    Akasbi, Miriam
    Nakamura, Hideki
    Szanto, Antonia
    Farris, A. Darise
    Wang, Li
    Mandl, Thomas
    Gattamelata, Angelica
    Kilic, Levent
    Pirkmajer, Katja Perdan
    Abacar, Kerem
    Tufan, Abdurrahman
    de Vita, Salvatore
    ECLINICALMEDICINE, 2023, 61
  • [22] Prevalence, Risk Factors, Clinical Features, and Outcome of Influenza-Associated Pulmonary Aspergillosis in Critically Ill Patients
    Lu, Lawrence Y.
    Lee, Hui Min
    Burke, Andrew
    Li Bassi, Gianluigi
    Torres, Antoni
    Fraser, John F.
    Fanning, Jonathon P.
    CHEST, 2024, 165 (03) : 540 - 558
  • [23] Clinical factors associated with pulmonary aspergillosis in patients with chronic obstructive pulmonary disease
    Molinos-Castro, Sonia
    Pesqueira-Fontan, Paula M.
    Rodriguez-Fernandez, Sergio A.
    Rodriguez-Framil, Montserrat
    Barbeito-Castineiras, Gema B.
    Carmen Gayol-Fernandez, M.
    Manuel Varela-Garcia, Pablo
    Manuel Padin-Paz, Emilio
    Rial-Rama, Pilar
    Perez del Molino-Bernal, Maria Luisa
    Garcia-Suarez, Flor
    Antonio Diaz-Peromingo, Jose
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2020, 38 (01): : 4 - 10
  • [24] The importance of risk factors for the prediction of patients with invasive pulmonary aspergillosis
    Kaya, Selcuk
    Gencalioglu, Eda
    Sonmez, Mehmet
    Koksal, Iftihar
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2017, 63 (09): : 764 - 770
  • [25] Prognostic factors and outcomes of invasive pulmonary aspergillosis, a retrospective hospital-based study
    Chen, Wei-Che
    Chen, I-Chieh
    Chen, Jun -Peng
    Liao, Tsai-Ling
    Chen, Yi-Ming
    PEERJ, 2024, 12
  • [26] Prevalence, Risk Factors, and Mortality of Invasive Pulmonary Aspergillosis in Patients with Anti-MDA5+Dermatomyositis: A Retrospective Study in China
    Chen, Xixia
    Lin, Sang
    Jin, Qiwen
    Zhang, Lu
    Jiang, Wei
    Lu, Xin
    Wang, Guochun
    Ge, Yongpeng
    JOURNAL OF INFLAMMATION RESEARCH, 2024, 17 : 3247 - 3257
  • [27] The epidemiological characteristics of invasive pulmonary aspergillosis and risk factors for treatment failure: a retrospective study
    Wang, Yun
    Cui, Xiaoman
    Tian, Ruixin
    Wang, Ping
    BMC PULMONARY MEDICINE, 2024, 24 (01):
  • [28] Mortality outcomes associated with invasive aspergillosis among acute exacerbation of chronic obstructive pulmonary disease patient population
    Mir, Tanveer
    Uddin, Mohammed
    Khalil, Amir
    Lohia, Prateek
    Porter, Lekiesha
    Regmi, Neelambuj
    Weinberger, Jarrett
    Koul, Parvaiz A.
    Soubani, Ayman O.
    RESPIRATORY MEDICINE, 2022, 191
  • [29] Risk factors and treatment outcomes in patients with chronic pulmonary aspergillosis
    Agarwal, Kshitij
    Chowdhary, Anuradha
    Rahman, M.
    Chaudhry, Anil
    Gaur, S. N.
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [30] Risk factors and clinical impact of COVID-19-associated pulmonary aspergillosis: multicenter retrospective cohort study
    Lee, Raeseok
    Cho, Sung-Yeon
    Lee, Dong-Gun
    Ahn, Hyojin
    Choi, Hyeah
    Choi, Su-Mi
    Choi, Jae-Ki
    Choi, Jung-Hyun
    Kim, Shin Young
    Kim, Youn Jeong
    Lee, Hyo-Jin
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2022, 37 (04) : 851 - +